Spleen Tyrosine Kinase Targeting in Hematological Disorders
Summary
Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein kinase central to signal transduction downstream of immunoreceptors in haematopoietic cells. Through the B-cell receptor (BCR) and Fc receptor pathways, Syk mediates proliferation, survival and migration signals in both normal and malignant lymphoid lineages. Dysregulated Syk activity contributes to diverse haematological disorders, notably B-cell malignancies such as chronic lymphocytic leukaemia and non-Hodgkin lymphomas, and immune cytopenias. The development of orally bioavailable small-molecule Syk inhibitors has transformed therapeutic strategies, with first-generation agents demonstrating proof of principle in rheumatoid arthritis and immune thrombocytopenia, and more selective second-generation compounds showing efficacy in relapsed or refractory B-cell cancers. Combination regimens with PI3K or BTK inhibitors are under active investigation to overcome microenvironmental resistance and improve remission durability. Despite challenges including adverse events and kinase selectivity, Syk targeting remains a promising approach to modulate aberrant immune signalling, offering a precision-therapy avenue in haematology.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Spleen Tyrosine Kinase Targeting in Hematological Disorders publication trend
The graph below shows the total number of articles in spleen tyrosine kinase targeting in hematological disorders across all publications each year (not limited to Nature Index journals).
Technical terms
Spleen tyrosine kinase (Syk): A cytosolic non-receptor protein kinase central to receptor-mediated signalling in haematopoietic cells.
B-cell receptor (BCR): A membrane immunoglobulin complex that initiates intracellular signalling upon antigen binding.
Chronic lymphocytic leukaemia (CLL): A B-cell malignancy characterised by clonal accumulation of mature lymphocytes.
BTK inhibitor: A small molecule targeting Bruton’s tyrosine kinase to block BCR signalling.
PI3K inhibitor: A compound that inhibits phosphoinositide 3-kinase, affecting cell growth and survival pathways.
References
- Syk inhibitors in clinical development for hematological malignancies. Journal of Hematology & Oncology (2017).
- Targeting Syk in Autoimmune Rheumatic Diseases. Frontiers in Immunology (2016).
- Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells. Oncotarget (2016).
- SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia. Journal of Cancer Therapy (2013).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.